Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.63 |
| ▸ | PLK1 | P53350 | 5/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.53 |
| ▸ | ICMT | O60725 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28174742 | 0.89 | CDC25A (0.66) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL13240042 | 0.86 | ICMT (0.49) | CDC25AMCL1ICMTALDH1A1KDM4E | |
| SCHEMBL2465449 | 0.83 | CDC25A (0.68) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL15747715 | 0.82 | CDC25A (0.80) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL29379289 | 0.80 | CDC25A (0.68) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL15747729 | 0.80 | CDC25A (0.90) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL29376139 | 0.79 | CDC25A (0.67) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL3743075 | 0.79 | CDC25A (0.70) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL28369902 | 0.78 | CDC25A (0.66) | CDC25APLK1MCL1ICMTALDH1A1 | |
| SCHEMBL2429439 | 0.78 | CDC25A (0.97) | CDC25APLK1MCL1ICMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CDC25A 2424/4885PLK1 1683/4885MCL1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.